LAZCLUZE - (80MG, 240MG ; Tablet)

Generic Name	LAZERTINIB MESYLATE	**Innovator**	Janssen Pharma
Dosage	80MG, 240MG ; Tablet	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	Less Than 5	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	LAZCLUZE is a kinase inhibitor indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.		
Complexities	Yes		

Chronology Of Events
Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary
Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status
Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition
Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events
Please Contact contact@researchdelta.com to get Detailed Information.